Trial Profile

A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capmatinib (Primary) ; Digoxin; Rosuvastatin
Indications Adenocarcinoma; Bladder cancer; Colon cancer; Intestinal cancer; Liver cancer; Lung cancer; Malignant melanoma; Mouth neoplasm; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Rectal cancer; Renal cancer; Solid tumours; Uterine cancer
Focus Pharmacokinetics
Sponsors Novartis; Novartis Pharmaceuticals

09 Dec 2020 Results published in the British Journal of Clinical Pharmacology
26 May 2017 Status changed from active, no longer recruiting to completed.
04 Apr 2017 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com